---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-076568"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2024-07-01T23:59:59+00:00"
generated_at: "2026-06-01T00:01:10.031016+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# uniQure sells Lexington manufacturing facility to Genezen for $25M, reduces cash burn $40M/year

## Summary
- Consideration $25M: $12.5M of Series C preferred stock and $12.5M convertible note (8%, 63-month maturity).
- Genezen to manufacture HEMGENIX commercial supply; CEO Matt Kapusta joins Genezen board after close.
- Company expects to reduce annual cash burn by ~$40M and repay $50M debt, saving interest expense.
- Majority of Lexington employees offered jobs at Genezen; transaction expected to close early Q3 2024.

## SEC filing metadata
- accession: 0001104659-24-076568
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2024-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465924076568/0001104659-24-076568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465924076568/tm2418608d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-076568
- JSON: https://secwatch.observer/filing/0001104659-24-076568.json
- Plain text: https://secwatch.observer/filing/0001104659-24-076568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.